Inclusion Criteria:

          -  Histologically confirmed advanced (not amenable to curative surgery or radiation
             therapy) or metastatic (AJCC Stage IV) renal cell carcinoma with a clear-cell
             component.

          -  Intermediate- or poor-risk RCC as defined by International Metastatic RCC Database
             Consortium (IMDC) criteria.

          -  Measurable disease per RECIST 1.1 as determined by the Investigator.

          -  Karnofsky Performance Status (KPS) ≥ 70%.

          -  Adequate organ and marrow function.

        Exclusion Criteria:

          -  Prior systemic anticancer therapy for unresectable locally advanced or metastatic RCC
             including investigational agents.

          -  Uncontrolled, significant intercurrent or recent illness including, but not limited to
             serious cardiovascular disorders (including uncontrolled hypertension defined as
             sustained blood pressure (BP) > 150 mm Hg systolic or > 90 mm Hg diastolic despite
             optimal antihypertensive treatment), GI disorders associated with high risk for
             perforation or fistula formation, tumors invading GI tract, bowel obstruction,
             intra-abdominal abscess, clinically significant bleeding events, cavitating pulmonary
             lesions, or lesions invading major pulmonary blood vessels.

          -  Other clinically significant disorders such as:

               -  Autoimmune disease that has been symptomatic or required treatment within the
                  past two years from the date of randomization.

               -  Any condition requiring systemic treatment with either corticosteroids (> 10 mg
                  daily prednisone equivalent) or other immunosuppressive medications within 14
                  days of randomization.

               -  Active infection requiring systemic treatment. Acute or chronic hepatitis B or C
                  infection, known human immunodeficiency virus (HIV) or acquired immunodeficiency
                  syndrome (AIDS)-related illness, or known positive test for tuberculosis
                  infection where there is clinical or radiographic evidence of active myobacterial
                  infection.

               -  Known history of COVID-19 unless the subject has clinically recovered from the
                  disease at least 30 days prior to randomization.

          -  Major surgery (eg, nephrectomy, GI surgery, removal or biopsy of brain metastasis)
             within 4 weeks prior to randomization. Minor surgeries within 10 days prior to
             randomization. Subjects must have complete wound healing from major or minor surgery
             before randomization.

          -  Any other active malignancy at time of randomization or diagnosis of another
             malignancy within 3 years prior to randomization that requires active treatment,
             except for locally curable cancers that have been apparently cured, such as basal or
             squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the
             prostate, cervix, or breast.